Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ILK | Q13418 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27399288 | 0.86 | NPC1 (0.43) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| SCHEMBL20651365 | 0.84 | NPC1 (0.46) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| SCHEMBL7219825 | 0.82 | DYRK1A (0.45) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| SCHEMBL30209148 | 0.82 | LOXL2 (0.65) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| SCHEMBL8461410 | 0.82 | LOXL2 (0.47) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| SCHEMBL4583713 | 0.82 | LOXL2 (0.65) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| SCHEMBL7223517 | 0.82 | NPC1 (0.63) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| Hydrochloric Acid SCHEMBL9335118 | 0.81 | AHR (0.44) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| Phosphine SCHEMBL9339078 | 0.81 | LOXL2 (0.46) | DYRK1AHDAC6LOXL2F2RL3AKR1B1 | |
| SCHEMBL201370 | 0.80 | DYRK1A (0.46) | DYRK1AHDAC6LOXL2AKR1B1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-05-22 | — | — | US | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024137852-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-06-06 | — | — | US | disclosed |
| CN-115160339-B | Aldose reductase inhibitors and methods of use thereof | 纽约市哥伦比亚大学理事会 | 2024-05-14 | — | — | CN | disclosed |
| EP-0795550-A1 | Aniline derivatives having herbicidal activity their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
| EP-0492667-B1 | 1,4-Benzothiazine-2-acetic acid derivatives, processes for production thereof and their use | GREEN CROSS CORP (JP) | 1996-04-17 | — | — | EP | disclosed |
| EP-0644194-A1 | PYRIDOTHIAZINEACETIC ACID COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-5330997-A | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1994-07-19 | — | — | US | disclosed |
| US-5252571-A | 1,4-benzothiazine-2-acetic acid derivatives | SAPPORO BREWERIES LIMITED (JP) | 1993-10-12 | — | — | US | disclosed |
| US-5236945-A | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0325375-B1 | 1H-INDAZOLE-3-ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1992-08-12 | — | — | EP | disclosed |
| EP-0492667-A1 | 1,4-Benzothiazine-2-acetic acid derivatives, processes for production thereof and their use | THE GREEN CROSS CORPORATION (JP) | 1992-07-01 | — | — | EP | disclosed |
| WO-1989006651-A1 | 1H-INDAZOLE-3-ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0325375-A1 | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | DYRK1A 4217/4885HDAC6 2777/4885LOXL2 310/4885 |
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | DYRK1A 3857/4885HDAC6 3388/4885LOXL2 427/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | DYRK1A 2516/4885HDAC6 376/4885LOXL2 685/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | DYRK1A 2516/4885HDAC6 376/4885LOXL2 685/4885 |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | DYRK1A 2189/4885HDAC6 500/4885LOXL2 3533/4885 |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | DYRK1A 4217/4885HDAC6 2777/4885LOXL2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.